Retinal Vein Occlusion Market is valued at USD 1.27 Billion in 2017 and expected to reach USD 3.23 Billion by 2027 with the CAGR of 9.8% over the forecast period.
Global Retinal Vein Occlusion Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Increasing prevalence of diabetes, as well as rising incidence of glaucoma, lymphoma, and multiple myeloma across the globe are expected to boost the Retinal vein occlusion market.
Retinal vein occlusion occurs due to blood clot in retinal vein which obstruct the blood flow to retina. It may also cause due to the narrow retinal veins which limits the blood flow to retina. Retinal vein occlusion is one of the most common causes of visual impairment on a global level. The blood clot led to the retinal vein blockage which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. There are two major types of retinal vein occlusion which includes blockage of the central retinal vein causes due to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) causes due to the blockage of smaller branches of veins of the retina. The major causes of retinal vein occlusion are atherosclerosis, hypertension, and eye conditions such as glaucoma and vitreous hemorrhage.
The Global Retinal Vein Occlusion Market has been segmented into condition, type, diagnosis, treatment, end-user region & country level. By type, the market has been segmented into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Based on the condition, the market has been divided into ischemic and non-ischemic. Based on diagnosis, the market has been segmented into fundoscopic examination, optical coherence tomography (OCT), fluorescein angiography, and others. By treatment, the market has been classified as anti-vascular endothelial growth factor drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, laser therapy, and others. By end-user, the retinal vein occlusion market is classified into hospitals, ophthalmic clinics & research centers, and others.
The regions covered in Global Retinal Vein Occlusion Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Retinal Vein Occlusion Market is sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global Retinal Vein Occlusion Market reports cover prominent players like ZEIS, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Novartis AG, NIDEK CO., LTD, Allergan PLC, Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., Bayer, Lumenis and others.
News: Development of new capase-9 inhibitor based eye drops to prevent the vision loss caused due to retinal vein occlusion
June 29th, 2020; Researchers of Columbia University Irving medical center has developed a new eye drop which will prevent vision loss after retinal vein occlusion, a important cause of blindness for millions of adults worldwide. The eye drops consist of highly selective capase-9 inhibitor which improves the blood flow, reduce swelling along with reduced neuronal damage. The researchers are preparing for human clinical trial phase 1.
Increasing prevalence of ophthalmic disorders on a global level followed by the growth of geriatric population is expected to anticipate the growth of global retinal vein occlusion market. Additionally, surge in awareness about ophthalmic disorders, improved health care infrastructure, and technological advancements, along with upcoming new treatments are also expected to fuel the growth of global retinal vein occlusion market. Furthermore, increasing incidence of atherosclerosis and diabetes that are recognized as important aspects causing retinal vein occlusion are the key factors driving the growth of the market. Moreover, expanding patient pool suffering from glaucoma, lymphoma, and myeloma is also expected to contribute the growth of retinal vein occlusion market.
However, high cost of treatment and side-effects associated with these treatments are estimated to hamper the market growth over the forecast period. On the other hand, surge in research and investment for the development of safe and economical treatments by market players are expected to create ample opportunities in the market.
Global Retinal Vein Occlusion Market: by Type
Global Retinal Vein Occlusion Market: by Condition
Global Retinal Vein Occlusion Market: by Diagnosis
Global Retinal Vein Occlusion Market: by Treatment
Global Retinal Vein Occlusion Market: by End User
North America is expected to direct the market growth, owing to the increasing prevalence of diabetes, and increasing incidence of diseases such as glaucoma, lymphoma, and multiple myeloma. According to the Centers for Disease Control and Prevention (CDC) in 2017, around 2.7 million people suffer from glaucoma in the US. Similarly, as per American Cancer Society 2018 report, there were around 30,770 new cases of multiple myeloma was diagnosed in the US.
Europe is the second largest region followed by North America in terms of market share. This growth is attributed by various factors such as presence of huge geriatric population along with high healthcare spending. For instance, as per the Organization for Economic Co-operation and Development (OECD) in 2017, the healthcare spending in Germany was USD 5,728 per capita, and the total healthcare spending was around USD 47,1637 million.
The Asia-Pacific region is expected to be the fastest developing region over the forecast period owing to presence of large geriatric population susceptible to various ophthalmic disorders. Moreover, development of healthcare infrastructure as well rising awareness among people with regards to ophthalmic disorders is likely to amplify the market growth in the near future.
Report Analysis | Details |
---|---|
Historical data | 2015 - 2020 |
Forecast Period | 2021 - 2027 |
Market Size in 2020: | USD 1.27 Billion |
Base year considered | 2020 |
Forecast Period CAGR %: | 9.80 % |
Market Size Expected in 2027: | USD 3.23 Billion |
Tables, Charts & Figures: | 175 |
Pages | 200 |
Key Players/Companies | ZEIS, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Novartis AG, NIDEK CO., LTD, Allergan PLC, Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., Bayer, Lumenis and others |
Segments Covered | By Type, By Condition, By Diagnosis, by Treatment, by End User |
Regional Analysis | North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa |
Key Benefits for Global Retinal Vein Occlusion Market Report:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Frequently Asked Questions (FAQ) :
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®